China's BeiGene doses first patient in BGB-3111, BGB-A317 PhI

China flag

Beijing-based oncology biotech BeiGene said it has dosed the first patient in a Phase I clinical trial for a combination of candidates--BGB-3111 and BGB-A317--aimed at B-cell malignancies as the firm ramps up pipeline work following a successful IPO at the start of the year.

BGB-3111, a Bruton’s tyrosine kinase (BTK) inhibitor, and BGB-A317, a PD-1 antibody, are internal candidates developed by BeiGene. BGB-3111 is the first BTK inhibitor to enter the clinic under China FDA guidelines and after the U.S. FDA approved an IND application for the candidate in June last year--a first for any of the company's early-stage candidates.

The combination trial is a multi-center dose escalation and expansion effort among 25 patients in Australia to assess safety, tolerability, pharmacokinetics, and anti-tumor activities, the company said in a release.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The biotech is also studying another combination of BGB-A317 with PARP inhibitor BGB-290.

“We have presented initial clinical data on both of these candidates as single agents," Eric Hedrick, interim chief medical officer at BeiGene said.

“We believe the combination of BGB-3111 and BGB-A317 in clinical trials has been well-supported by compelling preclinical data. Additionally, we believe ownership of both components in the combination regimen puts us in an advantageous position to develop the regimen to its full potential.”

- here's the release

Related Articles:
China's BeiGene reports positive initial PhI data on BGB-283
BeiGene comes in at top end of range in Nasdaq IPO, raising $158.4M
BeiGene approved to start China leg of global BTK inhibitor trial
China's BeiGene gets U.S. FDA IND nod on oncology candidate BGB-3111